Page 58 - GTM-4-2

Global Translational Medicine SPION for cancer theranostics

Magnetic drug delivery: Where the field is going. Front nanoparticle uptake and intracellular doxorubicin release.
Chem. 2018;6:619-626. ACS Nano. 2013;7:10175-10189.
doi: 10.3389/fchem.2018.00619 doi: 10.1021/nn404407g
69. Bhuyan T, Singh AK, Dutta D, Unal A, Ghosh SS, 76. Ling Y, Wei K, Luo Y, Gao X, Zhong S. Dual docetaxel/
Bandyopadhyay D. Magnetic field guided chemotaxis superparamagnetic iron oxide loaded nanoparticles for both
of Mushbots for targeted anticancer therapeutics. ACS targeting magnetic resonance imaging and cancer therapy.
Biomater Sci Eng. 2017;3:1627-1640. Biomaterials. 2011;32:7139-7150.
doi: 10.1021/acsbiomaterials.7b00086 doi: 10.1016/j.biomaterials.2011.05.089
70. Mai BT, Fernandes S, Balakrishnan PB, Pellegrino T. 77. Reczyńska K, Marszałek M, Zarzycki A, et al.
Nanosystems based on magnetic nanoparticles and Superparamagnetic iron oxide nanoparticles modified with
thermoorph responsive polymers: An update and future silica layers as potential agents for lung cancer treatment.
perspectives. Acc Chem Res. 2018;51:999-1013. Nanomaterials. 2020;10:1076.
doi: 10.1021/acs.accounts.7b00549 doi: 10.3390/nano10061076
71. Chen Z, Kankala RK, Long L, Xie S, Chen A, Zou L. 78. Horvat NK, Chocarro S, Marques O, et al.
Current understanding of passive and active targeting Superparamagnetic iron oxide nanoparticles reprogram the
nanomedicines to enhance tumor accumulation. Coord tumor microenvironment and reduce lung cancer regrowth
Chem Rev. 2023;481:215051. after crizotinib treatment. ACS Nano. 2024;18:11025-11041.
doi: 10.1016/j.ccr.2023.215051 doi: 10.1021/acsnano.3c08335
72. Wahajuddin, Arora S. Superparamagnetic iron oxide 79. Wang ZL, Qiao RR, Tang NG, et al. Active targeting
nanoparticles: Magnetic nanoplatforms as drug carriers. Int theranostic iron oxide nanoparticles for MRI and magnetic
J Nanomed. 2012;7:3445-3471. resonance-guided focused ultrasound ablation of lung
doi: 10.2147/IJN.S30320 cancer. Biomaterials. 2017;127:25-35.
73. Alexiou C, Arnold W, Klein RJ, et al. Locoregional cancer doi: 10.1016/j.biomaterials.2017.02.037
treatment with magnetic drug targeting. Cancer Res. 80. Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery
2000;60:6641-6648. systems: Recent developments and future prospects.
74. Kim J, Lee JE, Lee JH, et al. Designed fabrication of J Nanobiotechnol. 2018;16(71):1-33.
a multifunctional polymer nanomedical platform for doi: 10.1186/s12951-018-0392-8
simultaneous cancer- targeted imaging and magnetically
guided drug delivery. Adv Mater. 2008;20:478-483. 81. Available from: https://www.fda.gov/drugs/
resources-information-approved-drugs/fda-approves-
doi: 10.1002/adma.200701726 datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-
75. Basuki JS, Duong HTT, Macmillan A, et al. Using fluorescence hr-positive-her2-negative-breast cancer [Last accessed on
lifetime imaging microscopy to monitor theranostic 2025 Jan 17].

Volume 4 Issue 2 (2025) 50 doi: 10.36922/gtm.8464